HEX17(Neumifil): an intranasal respiratory biotherapeutic with broad-acting antiviral activity

Jane A Potter*, Angus Aitken, Lei Yang, Jennifer Hill, Antoni Tortajada, Julia L Hurwitz, Bart G Jones, Nadiawati Alias, Mingkui Zhou, Helen Connaris*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Broad-acting antiviral strategies to prevent respiratory tract infections are urgently required. Emerging or re-emerging viral diseases caused by new or genetic variants of viruses such as influenza viruses (IFVs), respiratory syncytial viruses (RSVs), human rhinoviruses (HRVs), parainfluenza viruses (PIVs) or coronaviruses (CoVs), pose a severe threat to human health, particularly in the very young or old, or in those with pre-existing respiratory conditions such as asthma or chronic obstructive pulmonary disease (COPD). Although vaccines remain a key component in controlling and preventing viral infections, they are unable to provide broad-spectrum protection against recurring seasonal infections or newly emerging threats. HEX17 (aka Neumifil), is a first-in-class protein-based antiviral prophylactic for respiratory viral infections. HEX17 consists of a hexavalent carbohydrate-binding module (CBM) with high affinity to sialic acids, which are typically present on terminating branches of glycans on viral cellular receptors. This allows HEX17 to block virus engagement of host receptors and inhibit infection of a wide range of viral pathogens and their variants with reduced risk of antiviral resistance. As described herein, HEX17 has demonstrated broad-spectrum efficacy against respiratory viral pathogens including IFV, RSV, CoV and HRV in multiple in vivo and in vitro studies. In addition, HEX17 can be easily administered via an intranasal spray and is currently undergoing clinical trials.
Original languageEnglish
Article number105945
Number of pages9
JournalAntiviral Research
Volume228
Early online date22 Jun 2024
DOIs
Publication statusPublished - Aug 2024

Keywords

  • Broad-spectrum antiviral
  • Respiratory syncytial virus
  • Rhinovirus
  • Influenza
  • Carbohydrate-binding module
  • Coronavirus

Fingerprint

Dive into the research topics of 'HEX17(Neumifil): an intranasal respiratory biotherapeutic with broad-acting antiviral activity'. Together they form a unique fingerprint.

Cite this